Harvard Business Review

AUGUST 17, 2012

Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. What's more, these are markets that traditional developed market firms are increasingly targeting for their own growth goals. and other traditionally developed markets. laç Ticaret Anonim ?irketi

Company 12

Company Pharmaceuticals Business Model Fixed Costs 12

Harvard Business Review

JULY 27, 2017

Among the 30 top companies in seven of the largest industries, almost half had a VC-fueled accelerator in 2015, up from just 2% in 2010. And the fixed cost from “touchpoint-to-pilot” are immense. In addition, top startups are heavily oversubscribed, and competition to get into a deal is fierce.

Venture Capitalist 8

Venture Capitalist Meyer Innovation Fixed Costs 8

Harvard Business Review

JANUARY 5, 2017

It’s not that the media sets out to be sensationalist; its business model leads it in that direction. Two developments bear noting. The media’s bias toward big events stems from three features of its economics: Fixed costs. Fixed costs have always been central to the economics of media.

Media 11

Media Advertising Fixed Costs Content 11